Celldex (CLDX) Price & Analysis

Compare

1,243 Followers

CLDX Stock Chart & Stats

$26.44

-$0.90(-3.26%)

At close: Jan 08 4:00 PM EST

$26.44

-$0.90(-3.26%)

Day’s Range― - ―

52-Week Range$14.40 - $29.05

Previous CloseN/A

Volume733.18K

Average Volume (3M)867.64K

Market Cap

$1.76B

Enterprise Value$1.14B

Total Cash (Recent Filing)$583.22M

Total Debt (Recent Filing)$2.62M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Mar 02, 2026

EPS Estimate

-1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.01

Shares Outstanding66,449,470

10 Day Avg. Volume884,074

30 Day Avg. Volume867,640

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)2.18

Price to Sales (P/S)231.80

P/FCF Ratio-10.19

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue439.88

Enterprise Value/Gross Profit642.16

Enterprise Value/Ebitda-4.64

Forecast

1Y Price Target

$54.67

Price Target Upside106.77% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-3.66

Revenue Forecast (FY)$2.79M

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressCelldex's barzolvolimab showed profound benefits on multiple secondary measures such as angioedema, QoL, and UCT score, all while maintaining a tolerable safety profile.

Financial StabilityStrong cash balance and shrewd utilization of capital has positioned its multiple programs for success on the near and long term horizons; an underrated position in today's market.

Pipeline ExpansionCelldex's SCF and TSLP bispecific antibody, CDX-622, is being assessed in a three-part Phase I study with positive results reported from Part 1.

Bears Say

Cash Burn ConcernsAnnualized Cash Burn (M) $206.0.

Unresolved Scientific QuestionsThe scientific question remains on what mechanisms are causing urticaria in patients who don't respond to anti-KIT therapy.

Celldex News

Celldex price target lowered to $21 from $25 at Barclays

Barclays lowered the firm’s price target on Celldex (CLDX) to $21 from $25 and keeps an Underweight rating...

17d ago

CLDX

Celldex reports Q3 EPS ($1.01), consensus (89c)

“This quarter, Celldex (CLDX) continued to demonstrate our leadership in the field of mast cell biology, presenting exciting...

18d ago

CLDX

Celldex appoints Lawver as Chief Commercial Officer

Celldex (CLDX) announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Lawver is a...

18d ago

CLDX

Celldex announces additional data on barzolvolimab

Celldex (CLDX) announced new data on exploratory endpoints further demonstrating barzolvolimab’s ability to improve urticaria control from the...

22d ago

CLDX

Celldex presents results from Barzolvolimab Phase 2 Study in ColdU, SD

Celldex (CLDX) announced new data demonstrating sustained efficacy and a well tolerated safety profile over a 20 week...

22d ago

CLDX

Celldex announces initial positive results from Phase 1 trial of CDX-622

Celldex (CLDX) announced positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that...

29d ago

CLDX

Celldex’s Promising Clinical Progress and Strategic Initiatives Drive Buy Rating

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Celldex yesterday and set a price target of...

15d ago

CLDX

Celldex’s Promising Future: Strong Pipeline and Financial Position Drive Buy Rating

Celldex, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C....

17d ago

CLDX

Celldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of...

17d ago

CLDX

Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress

Celldex Therapeutics ( ($CLDX) ) has released its Q3 earnings. Here is a breakdown of the information Celldex...

17d ago

CLDX

Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position

TD Cowen analyst Yaron Werber has maintained their bullish stance on CLDX stock, giving a Buy rating on...

17d ago

CLDX

Celldex’s Promising Phase II Trial Results Justify Buy Rating

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Celldex, retaining the price target of $62.00....

21d ago

CLDX

Celldex’s Promising Phase 2 Trial Results and Strong Financial Position Support Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of...

22d ago

CLDX

Celldex’s Barzolvolimab Shows Promising Phase 2 Results, Justifying Buy Rating

Celldex, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C....

22d ago

CLDX

CLDX FAQ

What was Celldex Therapeutics Inc’s price range in the past 12 months?

Celldex Therapeutics Inc lowest stock price was $14.40 and its highest was $29.05 in the past 12 months.

What is Celldex Therapeutics Inc’s market cap?

Celldex Therapeutics Inc’s market cap is $1.76B.

When is Celldex Therapeutics Inc’s upcoming earnings report date?

Celldex Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 94 days.

How were Celldex Therapeutics Inc’s earnings last quarter?

Celldex Therapeutics Inc released its earnings results on Nov 10, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.9 by -$0.11.

Is Celldex Therapeutics Inc overvalued?

According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Celldex Therapeutics Inc pay dividends?

Celldex Therapeutics Inc does not currently pay dividends.

What is Celldex Therapeutics Inc’s EPS estimate?

Celldex Therapeutics Inc’s EPS estimate is -1.

How many shares outstanding does Celldex Therapeutics Inc have?

Celldex Therapeutics Inc has 66,449,470 shares outstanding.

What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?

Celldex Therapeutics Inc reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.9. Following the earnings report the stock price went up 7.499%.

Which hedge fund is a major shareholder of Celldex Therapeutics Inc?

Currently, no hedge funds are holding shares in CLDX

Celldex Stock Smart Score

Neutral

Fundamentals

Return on Equity

-32.44%

Trailing 12-Months

Asset Growth

-21.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Celldex Therapeutics Inc

Celldex Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics for the treatment of cancer and other diseases. The company specializes in creating monoclonal antibodies and immuno-oncology products, leveraging its proprietary technology platforms to advance its pipeline of candidates aimed at enhancing the immune system's ability to fight tumors. Celldex operates primarily within the healthcare sector, specifically in the biopharmaceutical industry, and is committed to delivering groundbreaking treatment options to improve patient outcomes.

Celldex (CLDX) Earnings & Revenues

Historic Earnings Reports

CLDX Stock 12 Month Forecast

Average Price Target

$54.67

▲(106.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","34":"$34","53":"$53","72":"$72","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,34,53,72,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.73,31.596923076923076,36.463846153846156,41.330769230769235,46.19769230769231,51.06461538461538,55.931538461538466,60.79846153846154,65.66538461538461,70.5323076923077,75.39923076923077,80.26615384615384,85.13307692307693,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.73,28.87923076923077,31.02846153846154,33.17769230769231,35.32692307692308,37.47615384615385,39.62538461538462,41.77461538461539,43.923846153846156,46.073076923076925,48.222307692307695,50.371538461538464,52.52076923076923,{"y":54.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.73,26.28923076923077,25.84846153846154,25.407692307692308,24.966923076923077,24.526153846153846,24.085384615384616,23.644615384615385,23.203846153846154,22.763076923076923,22.322307692307692,21.88153846153846,21.44076923076923,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >